ST-920 Market Summary

Key Factors Driving ST-920 Growth

1. Positive clinical results and potential kidney-function benefits

The Phase I/II STAAR study reported a positive mean annualized estimated glomerular filtration rate (eGFR) slope of 1.965 mL/min/1.73 m²/year at 52 weeks across 32 treated patients, based on the April 10, 2025 data cutoff. This finding suggests potential renal benefit in a disease associated with progressive kidney damage. The FDA agreed that the 52-week eGFR slope could serve as the primary basis for an accelerated-approval application, making the clinical results an important potential driver of adoption.

2. One-time administration and reduced treatment burden

Unlike conventional enzyme replacement therapy (ERT), which generally requires regular intravenous infusions, ST-920 is designed as a single intravenous infusion that may provide sustained enzyme production. In the STAAR study, all 18 patients who entered on ERT had discontinued it and remained off ERT at the February 2025 data update. If longer-term studies confirm durable benefit, ST-920 could reduce recurring infusion visits and treatment burden, strengthening its appeal to patients and healthcare providers.

3. Potential for durable enzyme production

ST-920 has demonstrated sustained α-Gal A activity, with elevated enzyme activity maintained for up to 4.5 years in the longest-followed patient in the data reported in February 2026. This supports the potential for a long-lasting treatment effect, although durability across a larger patient population and over longer periods still requires confirmation. A durable response could differentiate ST-920 from therapies requiring repeated administration.

4. Regulatory progress and potential earlier market entry

Sangamo initiated a rolling Biologics License Application (BLA) submission to the U.S. FDA in December 2025 and reported in March 2026 that its preclinical and clinical modules had been submitted for review. The candidate has also received FDA Orphan Drug, Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations. These milestones may support regulatory development and review, although they do not guarantee approval or a particular launch date.

5. Opportunity to address a rare but serious, multisystem disease

Fabry disease can damage the kidneys, heart, nervous system and other organs. Its classic form has historically been estimated to affect approximately 1 in 50,000 to 117,000 males, although screening studies suggest that later-onset forms may be more common. This creates a defined specialist-treatment population, with potential demand for therapies that can address the underlying enzyme deficiency. Commercial uptake will depend on diagnosis rates, patient eligibility, long-term outcomes and access to treatment.

ST-920 Recent Developments

In September 2026, PTC Therapeutics announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time administered AAV gene therapy for Fabry disease. A rolling BLA submission to FDA for accelerated approval of ST-920 is expected to be completed in Q4 2026.

“ST-920 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of ST-920 for potential indication like Fabry’s disease in the 7MM. A detailed picture of ST-920’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the ST-920 for potential indications. The ST-920 market report provides insights about ST-920’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ST-920 performance, future market assessments inclusive of the ST-920 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ST-920 sales forecasts, along with factors driving its market.

ST-920 Drug Summary

ST-920 is an investigational, liver-directed gene therapy originally developed by Sangamo Therapeutics and acquired by PTC Therapeutics in September 2026 for the treatment of adults with Fabry disease, a rare, inherited lysosomal storage disorder caused by mutations in the GLA gene that result in deficient alpha-galactosidase A (α-Gal A) enzyme activity and the accumulation of harmful substances, including globotriaosylceramide (Gb3), in multiple organs. ST-920 uses a recombinant adeno-associated virus serotype 2/6 (AAV2/6) vector to deliver a functional copy of the human GLA gene to liver cells, enabling them to produce and release functional α-Gal A enzyme into the bloodstream. The therapy is designed to reduce the accumulation of disease-associated substrates, potentially improve kidney and other organ function, and provide sustained therapeutic benefits following a single intravenous infusion, potentially reducing the need for lifelong, regularly administered enzyme replacement therapy. ST-920 has been evaluated in the Phase 1/2 STAAR clinical study, which has investigated its safety, tolerability, enzyme activity, renal function, and potential to reduce dependence on enzyme replacement therapy. In March 2026, Sangamo reported advancing the rolling submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) under the accelerated approval pathway, with completion of the submission expected in the fourth quarter of 2026 following its acquisition by PTC Therapeutics. The report provides ST-920’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ST-920 Market Report

The report provides insights into:

• A comprehensive product overview including the ST-920 MoA, description, dosage and administration, research and development activities in potential indication like Fabry’s disease.
• Elaborated details on ST-920 regulatory milestones and other development activities have been provided in ST-920 market report.
• The report also highlights ST-920‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The ST-920 market report also covers the patents information, generic entry and impact on cost cut.
• The ST-920 market report contains current and forecasted ST-920 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ST-920 market report also features the SWOT analysis with analyst views for ST-920 in potential indications.

Methodology

The ST-920 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ST-920 Analytical Perspective by DelveInsight

• In-depth ST-920 Market Assessment

This ST-920 sales market forecast report provides a detailed market assessment of ST-920 for potential indication like Fabry’s disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ST-920 sales data uptil 2034.

• ST-920 Clinical Assessment

The ST-920 market report provides the clinical trials information of ST-920 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ST-920 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ST-920 Market Potential & Revenue Forecast

• Projected market size for the ST-920 and its key indications
• Estimated ST-920 sales potential (ST-920 peak sales forecasts)
• ST-920 Pricing strategies and reimbursement landscape

ST-920 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ST-920 Market positioning compared to existing treatments
• ST-920 Strengths & weaknesses relative to competitors

ST-920 Regulatory & Commercial Milestones

• ST-920 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ST-920 Clinical Differentiation

• ST-920 Efficacy & safety advantages over existing drugs
• ST-920 Unique selling points

ST-920 Market Report Highlights

• In the coming years, the ST-920 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ST-920 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ST-920’s dominance.
• Other emerging products for Fabry’s disease are expected to give tough market competition to ST-920 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ST-920 in potential indications.
• Analyse ST-920 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ST-920 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ST-920 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of ST-920? How strong is ST-920’s clinical and commercial performance?
• What is ST-920’s clinical trial status in each individual indications such as Fabry’s disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ST-920 Manufacturers?
• What are the key designations that have been granted to ST-920 for potential indications? How are they going to impact ST-920’s penetration in various geographies?
• What is the current and forecasted ST-920 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ST-920 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ST-920 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is ST-920? What is the duration of therapy and what are the geographical variations in cost per patient?